Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
40
datasets available to search
ShareScore release 0.9.0
Dataset results
40 results for “olodaterol”
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic
ClinicalTrials.gov study NCT02296138. IPD Sharing: Not stated. Countries: 51. Publications: 4.
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
ClinicalTrials.gov study NCT01696058. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
ClinicalTrials.gov study NCT01964352. IPD Sharing: Not stated. Countries: 10. Publications: 4.
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
ClinicalTrials.gov study NCT02629965. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanter
ClinicalTrials.gov study NCT05127304. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
ClinicalTrials.gov study NCT01311661. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT01431274. IPD Sharing: Not stated. Countries: 25. Publications: 12.
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
ClinicalTrials.gov study NCT01533922. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
ClinicalTrials.gov study NCT02969317. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
ClinicalTrials.gov study NCT01533935. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
ClinicalTrials.gov study NCT01694771. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
ClinicalTrials.gov study NCT01525615. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT01559116. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
ClinicalTrials.gov study NCT04138758. IPD Sharing: NO. Countries: 1. Publications: 1.
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
ClinicalTrials.gov study NCT02006732. IPD Sharing: Not stated. Countries: 11. Publications: 4.
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT01431287. IPD Sharing: Not stated. Countries: 24. Publications: 12.
Data from: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
Purpose: In the absence of head-to-head clinical trials comparing the once-daily, long-acting beta2-agonists olodaterol and indacaterol for the treatment of chronic obstructive pulmonary disease (COPD), an indirect treatment comparison by systematic review and synthesis of the available clinical evidence was conducted. Methods: A systematic literature review of randomized, controlled clinical trials in patients with COPD was performed to evaluate the efficacy and safety of olodaterol and indacaterol. Network meta-analysis and adjusted indirect comparison methods were employed to evaluate treatment efficacy, using outcomes based on trough forced expiratory volume in 1 second (FEV1), Transition Dyspnea Index, St George's Respiratory Questionnaire total score and response, rescue medication use, and proportion of patients with exacerbations. Results: Eighteen trials were identified for meta-analysis (eight, olodaterol; ten, indacaterol). Olodaterol trials included patients of all severities, whilst indacaterol trials excluded patients with very severe COPD. Concomitant maintenance bronchodilator use was allowed in most olodaterol trials, but not in indacaterol trials. When similarly designed trials/data were analyzed for change from baseline in trough FEV1 (liters), the following mean differences (95% confidence interval) were observed: trials excluding concomitant bronchodilator: indacaterol 75 mcg versus olodaterol 5 mcg, –0.005 (–0.077 to 0.067), and indacaterol 150 mcg versus olodaterol 5 mcg, 0.020 (–0.036 to 0.077); trials with concomitant tiotropium: indacaterol 150 mcg versus olodaterol 5 mcg, 0.000 (–0.043 to 0.042). In sensitivity analyses of the full network, results for change from baseline in trough FEV1 favored indacaterol, but this dataset suffered from trial design heterogeneity. For the other endpoints investigated, no statistically significant differences were found when analyzed in the full network. Conclusion: When compared under similar trial conditions, olodaterol and indacaterol have similar efficacy in patients with COPD. This research highlights the importance of considering the concomitant COPD medication when evaluating treatment effects in COPD.
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
ClinicalTrials.gov study NCT01703845. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Relative Bioavailability of of Olodaterol and Ketoconazole
ClinicalTrials.gov study NCT01153711. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Japan Long-term Safety for Tiotropium Plus Olodaterol
ClinicalTrials.gov study NCT01536262. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.